In patients with CKD stages 1-4, SGLT2i therapy was independently associated with significant reductions in perirenal (β=0.447; 95% CI 0.211-0.682) and epicardial adipose tissue thickness.
Observational (n=189)
Does SGLT2 inhibitor therapy reduce epicardial and perirenal adipose tissue thickness in adults with CKD stages 1-4?
SGLT2 inhibitor therapy is associated with significant reductions in epicardial and perirenal adipose tissue thickness in patients with CKD, suggesting a potential tissue-level mechanism for their cardiorenal benefits.
Effect estimate: β 0.447 for ΔPRAT (95% CI 0.211-0.682)
p-value: p=<0.001
Background and hypothesis: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) provide consistent cardiorenal benefits; however, tissue-level mechanisms remain insufficiently characterized. We investigated whether SGLT2i were associated with longitudinal remodeling of organ-specific adipose depots in patients with chronic kidney disease (CKD). Methods: In this observational study cohort (ADIPO-CKD; NCT07309094), adults with CKD stages 1–4 underwent clinical, biochemical and ultrasound imaging assessment at baseline (T0) and 8-month follow-up (T8). Thus, epicardial (EAT) and perirenal adipose tissue (PRAT) thickness were measured. Changes over time between patients under SGLT2i treatment and those without (Non-SGLT2i) were assessed using repeated-measures ANOVA and multivariable linear regression models adjusted for age, sex, baseline estimated glomerular filtration rate (eGFR), diabetes status, concomitant glucagon-like peptide 1 (GLP-1) receptor agonist therapy, body mass index (BMI) and visceral fat area (VFA) changes. Results: Among 189 CKD patients (50 SGLT2i and 139 non-SGLT2i), SGLT2i therapy was associated with significant reductions in PRAT (1.28 ± 0.70 to 0.91 ± 0.61 cm; ΔPRAT −0.37 cm; p < 0.002) and EAT (0.57 ± 0.27 to 0.36 ± 0.14 cm; ΔEAT −0.21 cm; p < 0.012), whereas no significant changes were observed in the Non-SGLT2i group. In multivariable models, SGLT2i exposure remained independently associated with ΔPRAT (β = 0.447; 95% CI 0.211–0.682; p < 0.001; R2 = 0.371) and ΔEAT (β = 0.061; 95% CI 0.009–0.113; p < 0.021; R2 = 0.053), including adjustment for changes in BMI and VFA. These findings were accompanied by trends toward improvement in renal function and systemic inflammation biomarkers in the SGLT2i group, although these changes did not reach statistical significance. In a secondary analysis, dapagliflozin was significantly associated with PRAT reduction, whereas a significant association was found between empagliflozin and EAT decrease. Conclusions: In CKD stages 1–4, SGLT2i use was independently associated with reductions in EAT and PRAT. These findings support a potential link between organ-specific adipose tissue and cardiorenal disease; however, given the observational design, these results should be interpreted as associative and hypothesis-generating. Dedicated mechanistic and adequately powered studies are warranted to determine their clinical relevance.
Checa-Ros et al. (Sat,) conducted a observational in Chronic kidney disease (CKD) stages 1-4 (n=189). Sodium-glucose cotransporter 2 inhibitors (SGLT2i) vs. Non-SGLT2i was evaluated on Changes in perirenal adipose tissue (PRAT) and epicardial adipose tissue (EAT) thickness (β 0.447 for ΔPRAT, 95% CI 0.211-0.682, p=<0.001). In patients with CKD stages 1-4, SGLT2i therapy was independently associated with significant reductions in perirenal (β=0.447; 95% CI 0.211-0.682) and epicardial adipose tissue thickness.